Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

View:
Post by Chritters on Jan 22, 2021 9:42am

Kaly News

Robert Just announced they are going to start recycling Used Toilet paper!! Awesome News.
Comment by losingmyshirt on Jan 22, 2021 9:54am
??? I was told that Kaly was looking for funding for a new Dental Floss Ranch in Montana. This Used Toilet paper recycling would fit right in. To the Moon. Stay Hard Snap Crackle Poop
Comment by Bigginvestor on Jan 22, 2021 10:25am
great news our butt holes need the toilet paper for sure now . We all just been drilled harrrrd!!! Buy Rob
Comment by 011Peking on Jan 22, 2021 10:52am
Great. Thx for the bs. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities